Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 13, 2013 - Issue 4
Submit an article Journal homepage
202
Views
67
CrossRef citations to date
0
Altmetric
Review

Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries

Brian Godman Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland, UK. [email protected]; Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86, Stockholm, Sweden; National Institute for Science and Technology on Innovation on Neglected Diseases, Centre for Technological Development in Health, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil
,
Iain Bishop Public Health and Intelligence Strategic Business Unit, NHS National Services Scotland, Edinburgh, EH12 9EB, UK
,
Alexander E Finlayson King’s Centre for Global Health, Global Health Offices, Weston Education Centre, Cutcombe Road, SE5 9RJ, London, UK
,
Stephen Campbell Centre for Primary Care, Institute of Population Health, University of Manchester, M13 9PL, UK; NIHR Greater Manchester Primary Care Patient Safety Translational Research Centre, University of Manchester, Manchester M13 9PL, UK
,
Hye-Young Kwon Institute of Health and Environment, Seoul National University, 1 Gwanak-ro Gwanak-gu, Seoul 151–742, South Korea
&
Marion Bennie Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland, UK. [email protected]; Public Health and Intelligence Strategic Business Unit, NHS National Services Scotland, Edinburgh, EH12 9EB, UK
Pages 469-482 | Published online: 09 Jan 2014

References

  • Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France; implications for key stakeholder groups. Appl. Health Econ. Health Policy 8, 7–24 (2010).
  • Godman B, Wettermark B, Hoffman M et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev. Pharmacoecon. Outcomes Res. 9, 65–83 (2009).
  • Godman B, Shrank W, Andersen M et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev. Pharmacoecon. Outcomes Res. 10, 707–722 (2010).
  • Godman B, Abuelkhair M, Vitry A et al. Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GABI 1(2), 69–83 (2012).
  • Godman B, Bennie M, Baumgärtel C et al. Essential to increase the use of generics in Europe to maintain comprehensive healthcare? Farmeconomia 13 (Suppl. 3), 5–20 (2012).
  • Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, Gustafsson LL. Enhancing the rational use of new medicines across European healthcare systems – a position paper. Eur. J. Clin. Pharmacol. 64, 1137–118 (2008).
  • Malmström E, Godman B, Diogene E et al. Dabigatran – a case history demonstrating the need for comprehensive approaches to optimise the use of new drugs. Front. Pharmacol 4, 1–19 (2013).
  • Godman B, Malmstrom RE, Bennie M et al. Prescribing restrictions – a necessary strategy among some European countries to enhance future prescribing efficiency? Revi. Health Care 3, 5–16 (2012).
  • Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev. Pharmacoecon. Outcomes Res. 12, 125–130 (2012).
  • Godman B, Shrank W, Andersen M et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front. Pharmacol. 1(141), 1–16 (2011).
  • McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK; impact and implications. Expert Rev. Pharmacoecon. Outcomes Res. 10, 73–85 (2010).
  • Ferner R, Lenney W, Marriott J. Controversy over generic substitution. BMJ 340, c2548 (2010).
  • Duerden MG, Hughes DA. Generic and therapeutic substitutions in the UK: are they a good thing? Br. J. Clin. Pharmacol. 70(3), 335–341 (2010).
  • Vončina L, Strizrep T, Godman B et al. Influence of demand-side measures to enhance renin–angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 11, 469–479 (2011).
  • Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries─an overview. GABI J. 1(2), 93–100 (2012).
  • Kwon HY, Yang BM. Do generics really create savings on drug expenditures? Korean J. Health Econ. Policy 17(4), 23–42 (2011).
  • van Woerkom M, Piepenbrink JF, Godman B et al. Ongoing measures to enhance the efficiency of prescribing of PPIs and statins in The Netherlands; influence and future implications. J. Comp. Effectiveness Res. 1, 527–538 (2012).
  • Coma A, Zara C, Godman B et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan Region: impact and future direction. Expert Rev. Pharmacoecon. Outcomes Res. 9, 569–581 (2009).
  • Bauer M, Whybrow P, Angst J et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J. Biol. Psychiatry 3, 5–43 (2002).
  • Cohen A. The primary care management of anxiety and depression: a GP’s perspective. Adv. Psychiatr. Treat. 14, 98–105 (2008).
  • Barbui C, Hotopf M, Freemantle N et al. Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst. Rev. 4, CD002791 (2000).
  • Arroll B, Elley CR, Fishman T et al. Antidepressants versus placebo for depression in primary care. Cochrane Database Syst. Rev. 3, CD007954 (2009).
  • Baumgärtel C, Godman B, Malmström R, Andersen M et al. What lessons can be learned from the launch of generic clopidogrel? GABI 1(2), 58–68 (2012).
  • Araszkiewicz AA, Szabert K, Godman B, Wladysiuk M, Barbui C, Haycox A. Generic olanzapine: health authority opportunity or nightmare? Expert Rev. Pharmacoecon. Outcomes Res. 8, 549–555 (2008).
  • Alessi-Severini S, Honcharik PL, Simpson KD, Eleff MK, Collins DM. Evaluation of an interchangeability switch in patients treated with clozapine: a retrospective review. J. Clin. Psychiatry 67(7), 1047–1054 (2006).
  • Paton C. Generic clozapine: outcomes after switching. Br. J. Psychiatry 89, 184–185 (2006).
  • Bazire S, Burton V. Generic clozapine in schizophrenia: what is all the fuss about? Pharm. J. 173, 720–721 (2004).
  • Komossa K, Rummel-Kluge C, Schwarz S et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 1, CD006626 (2011).
  • Lieberman JA, Stroup T. Commentary – The NIM H-CAT IE Schizophrenia Study: What did we learn? Am. J. Psychiatry 168, 770–775 (2011).
  • Godman B, Bucsics A, Burkhardt T et al. Potential to enhance the prescribing of generic drugs in patients with mental health problems in Austria; implications for the future. Front. Pharmacol. 3, 198 (2013).
  • Parks J, Radke A, Parker G et al. Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr. Bull. 35, 931–936 (2009).
  • Godman B, Shrank W, Wettermark B et al. Use of generics – a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 3, 2470–2494 (2010).
  • Dylst P, Simoens S. Does the market share of generic medicines influence the price level? A European analysis. Pharmacoeconomics 29(10), 875–882 (2011).
  • Dylst P, Vulton A, Simoens S. The impact of reference pricing systems in Europe: a literature reviews and case studies. Expert Rev. Pharmacoecon. Outcomes Res. 11, 729–737 (2011).
  • Woodroffe R, Yao GL, Meads C et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol. Assess. 9(21), 1–179 (2005).
  • Rønning M, Blix HS, Harbø BT, Strøm H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose – are drug utilisation data comparable? Eur. J. Clin. Pharmacol. 56, 723–727 (2000).
  • Vlahovic-Palcevski V, Gantumur M, Radosevic N et al. Coping with changes in defined daily dose in longitudinal drug consumption databases. Pharm. World Sci. 32, 125–129 (2010).
  • Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking – an overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7, 137–147 (2009).
  • Pettersson B, Hoffmann M, Per Wändell P, Lars-Åke Levin L-A. Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. Health Policy 104, 84–91 (2012).
  • Fletcher A, Palmer A, Bulpitt C. Coughing with angiotensin converting enzyme inhibitors; how much of a problem? J. Hypertens 12, S43–S47 (1994).
  • Wettermark B, Godman B, Neovius M et al. Initial effects of a reimbursement restriction to improve the cost–effectiveness of antihypertensive treatment. Health Policy 94, 221–229 (2010).
  • Elliot H. Focus on the ONTARGET results. J. Hypertens 27, S8–S10 (2009).
  • McDowell S, Coleman J, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 332, 1177–1181 (2006).
  • Moon J, Flett A, Godman B, Grosso A, Wierzbicki A. Getting better value from the NHS drug budget. BMJ 342, 30–32 (2011).
  • Bennie M, Bishop I, Godman B, Campbell S, Miranda J, Finlayson A, Gustafsson LL. Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland? Qual. Prim. Care 21, 7–15 (2013).
  • Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst. Rev. 4, CD003822 (2008).
  • Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract. 62, 480–484 (2008).
  • Svanström H, Pasternak B, Hviid A. Association of treatment with losartan vs candersartan and mortality among patients with heart failure. JAMA 307, 1506–1512 (2012).
  • Bucsics A, Godman B, Burkhardt T et al. Influence of lifting prescribing restrictions for losartan on subsequent sartan utilisation patterns in Austria; implications for other countries. Expert Rev. Pharmacoecon Outcomes Res. 12, 809–819 (2012).
  • Simoens S, De Bruyn K, Miranda J, Bennie M, Malmström RE, Godman B. Measures to enhance ARB prescribing efficiency in Belgium following generic losartan: impact and implications for the future. J. Pharm. Health Serv. Res. 4, 173–181 (2013).
  • Godman B, Wettermark B, Miranda J et al. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries. Int. J. Clin. Pract. doi: 10.1111/ijcp.12130 (2013) (Eprint ahead of publication).
  • Godman B, Bennett K, Bennie M et al. Variable approaches to enhancing the prescribing of losartan once generics available; influence and future direction. Pharmacoepidemiol. Drug Safety 21(Suppl. 3), 295 (2012).
  • Godman B, Martin A, Tilstone J, Saleem N. Pharmacists appreciably improving sartan prescribing efficiency in the UK; implications for other classes and countries. Pharmacoepidemiol. Drug Safety doi: 10.1002/pds.3428 (2013).
  • Bennie M, Bishop I, Godman B et al. Are specific initiatives required to enhance the prescribing of generic atypical antipsychotics in Scotland?; International implications. Int. J. Clin. Pract. 67(2), 170–180 (2013).
  • Godman B, Persson M, Miranda J, Barbui B, et al. Can authorities take full advantage of the availability of generic atypical antipsychotic drugs? The situation in Sweden and implications for other countries. J. Pharm. Health Serv. Res. 4, 139–150 (2013).
  • Godman B, Bennett K, Bennie M et al. Are health authorities and health insurance companies taking full advantage of the availability of generic risperidone; implications for the future? Pharmacoepidemiol. Drug Safety 21(Suppl. 3), 55–56 (2012).
  • Bero LA, Grilli R, Grimshaw JM et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ 317, 465–468 (1998).
  • Barton S. Using clinical evidence. BMJ 322, 503–504 (2001).
  • Feely J, Bennett K. Epidemiology and economics of statin use. Ir. Med. J. 101, 188–191 (2008).
  • Olsson E, Sporrong SK. Pharmacists’ experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin. Int. J. Pharm. Pract. 6, 377–383 (2012).
  • Dylst P, Vulto A, Godman B, Simoens S. Generic medicines: solutions for a sustainable drug market? Appl. Health Econ. Health Policy doi:10.1007/s40258-013-0043-z (2013) (Epub ahead of print).
  • Garuoliene K, Godman B, Gulbinovič J, Wettermark B, Haycox A. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Expert Rev. Pharmacoecon. Outcomes Res. 11, 343–349 (2011).
  • Abuelkhair M, Abdu S, Godman B et al. Imperative to always consider multiple initiatives to maximise prescribing efficiency from generic availability: case history from Abu Dhabi. Expert Rev. Pharmacoecon. Outcomes Res. 12, 115–124 (2012).
  • Godman B, Paterson K, Malmstrom R et al. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev. Pharmacoecon. Outcomes Res. 12(4), 439–441 (2012).
  • Markovic-Pekovic V, Ranko Škrbić R, Godman B, Gustafsson LL. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Rev. Pharmacoecon. Outcomes Res. 5, 661–671 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.